Literature DB >> 1375484

Expression of pp60c-src in human small cell and non-small cell lung carcinomas.

N N Mazurenko1, E A Kogan, I B Zborovskaya, F L Kisseljov.   

Abstract

c-src protein was found in 60% of lung carcinomas (20 of 33 cases or primary tumours) by immunoblotting with a monoclonal antibody (Mab 327) and immunohistochemistry with serum from rabbits bearing tumours induced by Rous sarcoma virus. src protein expression was assessed in 4 small cell lung carcinomas and in an atypical carcinoid of neuroendocrine origin. However, pp60c-src was also found in non-small cell lung carcinomas: in 60-80% of adenocarcinomas and bronchiolo-alveolar cancers and in 50% of squamous cell carcinomas. In the squamous cell carcinomas, src protein was expressed more frequently in poorly differentiated than in well and moderately differentiated carcinomas. Expression of pp60c-src was not found in epithelial cells of histologically unchanged lung tissues. These results show that pp60c-src may be activated in human lung carcinomas of different histopathological types.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1375484     DOI: 10.1016/s0959-8049(05)80056-5

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  31 in total

1.  The human immunodeficiency virus protease inhibitor ritonavir inhibits lung cancer cells, in part, by inhibition of survivin.

Authors:  Anjaiah Srirangam; Monica Milani; Ranjana Mitra; Zhijun Guo; Mariangellys Rodriguez; Hitesh Kathuria; Seiji Fukuda; Anthony Rizzardi; Stephen Schmechel; David G Skalnik; Louis M Pelus; David A Potter
Journal:  J Thorac Oncol       Date:  2011-04       Impact factor: 15.609

2.  SRC tyrosine kinase inhibitor, m475271, suppresses subcutaneous growth and production of lung metastasis via inhibition of proliferation, invasion, and vascularization of human lung adenocarcinoma cells.

Authors:  Rui Zheng; Seiji Yano; Yuka Matsumori; Emiko Nakataki; Hiroaki Muguruma; Masanori Yoshizumi; Saburo Sone
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

3.  Aflatoxin B1 induces Src phosphorylation and stimulates lung cancer cell migration.

Authors:  Anguo Cui; Hui Hua; Ting Shao; Peiying Song; Qingbin Kong; Ting Luo; Yangfu Jiang
Journal:  Tumour Biol       Date:  2015-03-29

4.  Indole-3-carbinol inhibited tobacco smoke carcinogen-induced lung adenocarcinoma in A/J mice when administered during the post-initiation or progression phase of lung tumorigenesis.

Authors:  Xuemin Qian; Tamene Melkamu; Pramod Upadhyaya; Fekadu Kassie
Journal:  Cancer Lett       Date:  2011-07-02       Impact factor: 8.679

5.  Expression of c-Src and phospho-Src in epithelial ovarian carcinoma.

Authors:  Yong-Wen Huang; Chen Chen; Man-Man Xu; Jun-Dong Li; Juan Xiao; Xiao-Feng Zhu
Journal:  Mol Cell Biochem       Date:  2013-01-01       Impact factor: 3.396

6.  Tris DBA palladium overcomes hypoxia-mediated drug resistance in multiple myeloma.

Authors:  Pilar de la Puente; Feda Azab; Barbara Muz; Micah Luderer; Jack Arbiser; Abdel Kareem Azab
Journal:  Leuk Lymphoma       Date:  2015-11-16

7.  Chaperon-like Activation of Serum-Inducible Tryptophanyl-tRNA Synthetase Phosphorylation through Refolding as a Tool for Analysis of Clinical Samples.

Authors:  Elena L Paley
Journal:  Transl Oncol       Date:  2011-12-01       Impact factor: 4.243

8.  A phase II study of dasatinib in patients with chemosensitive relapsed small cell lung cancer (Cancer and Leukemia Group B 30602).

Authors:  Antonius A Miller; Herbert Pang; Lydia Hodgson; Nithya Ramnath; Gregory A Otterson; Michael J Kelley; Robert A Kratzke; Everett E Vokes
Journal:  J Thorac Oncol       Date:  2010-03       Impact factor: 15.609

9.  Src-Induced cisplatin resistance mediated by cell-to-cell communication.

Authors:  Elizabeth Peterson-Roth; Cathleen M Brdlik; Peter M Glazer
Journal:  Cancer Res       Date:  2009-04-07       Impact factor: 12.701

Review 10.  Src kinases as therapeutic targets for cancer.

Authors:  Lori C Kim; Lanxi Song; Eric B Haura
Journal:  Nat Rev Clin Oncol       Date:  2009-10       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.